We Finally Know How To Remove Plaque From Arteries

Main Ideas

• Arterial plaque may be reversible. Plaque was long thought to be something doctors could mainly slow or stabilize. The presenter argues that newer imaging research suggests intensive cholesterol-lowering treatment can also reduce existing plaque.
• LDL cholesterol and apoB are important causal risk factors. ApoB reflects the number of cholesterol-carrying particles that can enter artery walls. The presenter says lowering LDL and apoB should complement attention to other risks, such as blood pressure and insulin sensitivity.
• A higher calcium score does not necessarily mean treatment is failing. Statins may increase calcium deposits as plaque becomes more stable, even while more vulnerable, non-calcified plaque decreases. According to the video, a calcium score can rise while heart-attack risk falls.
• Combining cholesterol-lowering medicines may lower LDL more than a statin alone. Statins reduce cholesterol production in the liver, while ezetimibe reduces cholesterol absorption in the intestines. The presenter explains that these medicines work through different pathways.

Evidence and Studies Discussed

• PESA study: Researchers examined the arteries of middle-aged, non-smoking Spanish bank employees who generally had healthy weight, blood pressure, and blood sugar. Plaque was found in many participants, including some with otherwise ideal health measures. The presenter uses this study, along with genetic and treatment-trial evidence, to support the role of LDL and apoB in heart disease.
• Earlier imaging trials: A 2006 study of roughly 350 people with heart disease reportedly found an average plaque reduction of about 7–8% after two years of statin treatment. Later trials also found modest plaque regression in some patients, often examining only a section of one artery.
• EAS PAVE trial: In a trial involving more than 3,000 people with heart disease, the group assigned a lower LDL target—below 55 rather than around 70—had fewer serious cardiovascular events over three years: 6.6% versus 9.7%. Participants in the lower-target group often needed ezetimibe in addition to statins.
• Danish “Flow Promote” study: This small randomized study enrolled 104 people with newly diagnosed coronary artery narrowing who had not previously taken long-term statin treatment. Participants received either atorvastatin 40 mg or rosuvastatin 40 mg plus ezetimibe 10 mg. CT angiography was performed at the start of the study, and again at nine and 18 months.
  • LDL fell from about 120 to 70 mg/dL in the atorvastatin group, and to about 42 mg/dL in the combination-treatment group.
  • Total plaque volume reportedly fell by about 14% with atorvastatin and 21% with combination therapy.
  • Non-calcified, softer plaque fell by about 20% and 28%, respectively.
  • Calcified plaque increased by about half in both groups, which the presenter interprets as consistent with plaque stabilization.
  • The study’s primary outcome—blood flow through narrowed arteries—did not improve significantly. The plaque findings were therefore exploratory, rather than the main confirmed result.

Limitations and Cautions

• The Danish study was small, and participants knew which treatment they were receiving, although the person assessing the scans did not know their treatment group.
• Plaque measurements varied considerably when scans were repeated, making individual changes difficult to interpret. The presenter is more confident that plaque declined across the groups than in the precise difference between the two treatments.
• About one in five participants had their treatment changed during the study, mostly because of muscle pain or elevated liver enzymes. Only two stopped statins entirely.
• The presenter says very low blood LDL does not necessarily deprive cells of cholesterol because most cells can produce their own. He also cites studies that found no memory effects in a group taking strong cholesterol-lowering medication and no changes in sex or adrenal hormones at very low LDL levels.
• These findings do not establish a treatment plan for every individual. The video advises discussing medical decisions with a clinician.

Approach Advocated by the Presenter

The presenter describes the following general strategy for his clinic:

• Address diet and exercise while also assessing cholesterol-related risk.
• Aim for low apoB over the long term; he says his usual goal for many patients is below 50.
• Often begin with low-dose rosuvastatin, such as 5 mg, and add ezetimibe 10 mg if needed.
• Consider PCSK9 inhibitors for people who cannot tolerate statins.
• Use coronary calcium scans selectively, especially when a reluctant patient may be persuaded by seeing evidence of plaque, rather than waiting for a scan before taking preventive steps.

The presenter argues that increasing a statin dose has diminishing returns. In his account, rosuvastatin 5 mg lowers LDL by about 45%, while 40 mg lowers it by about 63%. He also cites a study in people with heart disease in which a moderate statin dose plus ezetimibe reportedly prevented heart attacks and strokes as effectively as higher-dose rosuvastatin, with fewer treatment changes due to side effects.

Speakers and Sources Featured

• Speaker: Dr. Brad Stanfield, the video’s narrator and presenter.
• Research and evidence referenced: The PESA study; Mendelian-randomization research; clinical trials of LDL/apoB lowering; a 2006 plaque-imaging study; the EAS PAVE trial; the Danish “Flow Promote” study; and an unnamed study of 3,780 people with heart disease comparing moderate-dose rosuvastatin plus ezetimibe with higher-dose rosuvastatin.
• Other sources or organizations mentioned: The Novo Nordisk Foundation, identified as the Danish study’s funder; Cost Plus Drugs, mentioned for medication pricing; and an unnamed lead author of the Danish study.